Comparison between plasma, serum and cerebrospinal fluid glial fibrillary acidic protein in Alzheimer’s Disease and Dementia with Lewy bodies and the effect of age and sex on diagnostic performance

Glial fibrillary acidic protein (GFAP) is a novel Alzheimer’s Disease (AD) biomarker that associates with amyloid pathology and pathology‐related changes can be detected in different biofluids. We studied how the performance of GFAP to distinguish between controls, AD and dementia with Lewy bodies (DLB), depends on the studied biofluid (cerebrospinal fluid (CSF), serum or plasma) and the confounding effects of age or sex.